Caristo Diagnostics utilizes CaRi-Heart® technology to detect hidden inflammation in coronary arteries, enabling early diagnosis of heart diseases, stroke, and diabetes. This platform enhances preventive screening and optimizes treatment planning by providing individualized risk scores based on advanced imaging analysis.
Funding
$30.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HFounders
Product
Problem
Despite advancements in cardiac computed tomography angiography (CCTA), a significant number of patients experiencing cardiac events show no significant arterial narrowing, indicating that traditional diagnostic methods may overlook critical risk factors. Coronary inflammation, a key driver of heart attacks and strokes, often remains undetected in routine CCTA scans, leaving a substantial portion of at-risk individuals without timely intervention.
Solution
Caristo Diagnostics offers the CaRi-Heart® technology, an AI-assisted platform that quantifies coronary inflammation from routine CCTA scans, providing clinicians with a more comprehensive understanding of a patient's cardiac risk. By applying advanced AI algorithms to standard cardiac CT images, CaRi-Heart® generates a Fat Attenuation Index (FAI) Score™ that measures coronary inflammation, identifies vulnerable patients, and predicts the risk of future cardiac events. The CaRi-Heart® Analysis is supported by cloud-based software, providing clinicians with individualized risk scores and detailed reports to facilitate early diagnosis, preventive screening, and optimized treatment planning. This technology enables a shift from reactive treatment to proactive prevention, potentially reducing cardiac deaths and improving patient outcomes.
Target Audience
The primary target audience includes cardiologists, radiologists, and healthcare providers seeking advanced diagnostic tools for early detection and risk stratification of coronary artery disease, as well as pharmaceutical companies involved in developing and testing anti-inflammatory therapies for cardiovascular disease.
Features
- AI-driven analysis of routine cardiac CT scans to visualize and quantify coronary inflammation
- Proprietary Fat Attenuation Index (FAI) Score™ for measuring coronary inflammation
- Individualized risk scores integrating coronary inflammation status with standard clinical risk factors
- Coronary plaque-specific characterization and quantification
- Cloud-based software accessible from any scanner generating routine cardiac CT images
- Integration with anti-inflammatory treatments to reduce cardiovascular risk
- Prediction of fatal and non-fatal cardiac events independent of routine clinical risk scores
- CaRi-Plaque™ analysis for detailed plaque assessment